论文著作：
1.Zhang N, Zhao SS, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel biphenyl compound IMB-S7 ameliorates hepatic fibrosis in BDL rats by suppressing Sp1-mediated integrin αv expression. Acta Pharmacol Sin. 2020 May;41(5): 661- 669.
2.Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao YY, Huang R, Yu DK*, Shao RG*, He HW*. Costunolide represses hepatic fibrosis through WWP2-mediated Notch3 degradation. Br J Pharmacol. 2020 Jan;177(2):372-387.
3.Ge MX, Niu WX, Ren JF, Cai SY, Yu DK, Liu HT, Zhang N, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.Acta Pharmacologica Sinica. 2019 Jul;40(7):895-907.
4.Zhao SS, Li NR, Zhao WL, Liu H, Ge MX, Zhang YX, Zhao LY, You XF, He HW*, Shao RG*. D-chiro-inositol attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress, Acta Pharmacologica Sinica. 2018 Feb, 39(2): 213-221.
5.Ge M, Liu H, Zhang Y, Li N, Zhao S, Zhao W, Zhen Y, Yu J, He H*, Shao RG*. The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br J Pharmacol. 2017 May; 174(10):1147-1160.
6.Zhao S, Li N, Zhen Y, Ge M, Li Y, Yu B, He H*, Shao RG*. Protective effect of gastrodin on bile duct ligation-induced hepatic fibrosis in rats. Food Chem Toxicol. 2015 Oct 21;86:202-207.
7.Dong-ke YU, Cai-xia ZHANG, Shuang-shuang ZHAO, Sheng-hua ZHANG, Hao ZHANG, Shi-Ying CAI, Rong-guang SHAO, Hong-wei HE*, The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway. Acta Pharmacologica Sinica (2015) 36: 473–482.
8.Hongwei He, Albert Mennone, James L. Boyer, and Shi-Ying Cai. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct ligated rats and human hepatic cells. Hepatology. 2011 ;53(2):548-57.
何红伟
北京市
研究领域：
生物医药
研究方向：
肿瘤分子药理和肝脏疾病分子药理
所在单位：
中国医学科学院北京协和医学院
